Diagnostics industry warned over inaction on UN (United Nations) transport rules
This article was originally published in Clinica
Executive Summary
Despite earlier warnings of the implications that impending stricter transportation rules are threatening the market for diagnostic samples that have to be delivered to laboratories for testing, industry is still not taking the threat seriously and has not been active in lobbying for change. Yet, if the forthcoming rules agreed by the United Nations in December 2000 are not modified they could discourage doctors from taking samples that need to be transported for testing. The development, however, is likely to encourage more near-patient testing.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.